Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2011 1
2012 2
2013 1
2015 3
2016 2
2017 14
2018 36
2019 46
2020 42
2021 71
2022 46
2023 54
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

292 results

Results by year

Filters applied: . Clear all
Page 1
Ertugliflozin.
[No authors listed] [No authors listed] 2023 Sep 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Sep 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000032 Free Books & Documents. Review.
No information is available on the clinical use of ertugliflozin during breastfeeding. Ertugliflozin is 94% protein bound in plasma, so it is unlikely to pass into breastmilk in clinically important amounts. The manufacturer does not recommend ertugliflozin d …
No information is available on the clinical use of ertugliflozin during breastfeeding. Ertugliflozin is 94% protein bound in p …
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, Shih WJ, Gantz I, Terra SG, Cherney DZI, McGuire DK; VERTIS CV Investigators. Cannon CP, et al. N Engl J Med. 2020 Oct 8;383(15):1425-1435. doi: 10.1056/NEJMoa2004967. Epub 2020 Sep 23. N Engl J Med. 2020. PMID: 32966714 Clinical Trial.
BACKGROUND: The cardiovascular effects of ertugliflozin, an inhibitor of sodium-glucose cotransporter 2, have not been established. METHODS: In a multicenter, double-blind trial, we randomly assigned patients with type 2 diabetes and atherosclerotic cardiovascular disease …
BACKGROUND: The cardiovascular effects of ertugliflozin, an inhibitor of sodium-glucose cotransporter 2, have not been established. M …
Ertugliflozin for the treatment of type 2 diabetes.
Sharma R, Razdan K, Kuhad A, Kuhad A. Sharma R, et al. Drugs Today (Barc). 2019 Mar;55(3):167-175. doi: 10.1358/dot.2019.55.3.2904972. Drugs Today (Barc). 2019. PMID: 30938372 Review.
Food and Drug Administration (FDA) in December 2017 for treatment of T2DM as a monotherapy, and as part of two separate fixed-dose combination therapies with sitagliptin (Steglujan) and metformin (Segluromet). Ertugliflozin demonstrated roughly 100% bioavailability followi …
Food and Drug Administration (FDA) in December 2017 for treatment of T2DM as a monotherapy, and as part of two separate fixed-dose combinati …
Ertugliflozin: First Global Approval.
Markham A. Markham A. Drugs. 2018 Mar;78(4):513-519. doi: 10.1007/s40265-018-0878-6. Drugs. 2018. PMID: 29476348 Review.
Ertugliflozin and fixed-dose combinations of ertugliflozin and metformin (Segluromet) and ertugliflozin and sitagliptin (Steglujan) have recently been approved by the US FDA as an adjunct to diet and exercise to improve glycaemic control in adults with T2DM. …
Ertugliflozin and fixed-dose combinations of ertugliflozin and metformin (Segluromet) and ertugliflozin and sitagliptin …
Ertugliflozin as a monotherapy for the treatment of type 2 diabetes.
Hu J, Deng A, Zhao Y. Hu J, et al. Expert Opin Pharmacother. 2018 Nov;19(16):1841-1847. doi: 10.1080/14656566.2018.1525360. Epub 2018 Sep 24. Expert Opin Pharmacother. 2018. PMID: 30223693 Review.
Based on the available clinical trials of ertugliflozin as a monotherapy for T2DM, it could be found that ertugliflozin effectively improves the glycemic control, body weight and blood pressure of patients with a low risk of hypoglycemia. It is also found that er …
Based on the available clinical trials of ertugliflozin as a monotherapy for T2DM, it could be found that ertugliflozin effect …
Ertugliflozin in the treatment of type 2 diabetes mellitus.
Marrs JC, Anderson SL. Marrs JC, et al. Drugs Context. 2020 Nov 30;9:2020-7-4. doi: 10.7573/dic.2020-7-4. eCollection 2020. Drugs Context. 2020. PMID: 33293984 Free PMC article. Review.
This narrative review aims to present and discuss the efficacy, safety, cardiovascular (CV), and renal outcomes related to the use of ertugliflozin in T2D. Ertugliflozin has been evaluated in eight clinical trials (n=5248) with a focus on glycemic control. ...The fi …
This narrative review aims to present and discuss the efficacy, safety, cardiovascular (CV), and renal outcomes related to the use of ert …
Role of Ertugliflozin in the Management of Diabetes Mellitus.
Totade M, Gaidhane SA. Totade M, et al. Cureus. 2022 Nov 12;14(11):e31404. doi: 10.7759/cureus.31404. eCollection 2022 Nov. Cureus. 2022. PMID: 36523727 Free PMC article. Review.
As a standalone therapy or an adjunctive treatment, ertugliflozin seems to be a reliable and safe option.This narrative review seeks to report and analyze ertugliflozin's effectiveness, safety, cardiovascular (CV), and renal outcomes in T2DM. ...Additionally, ert …
As a standalone therapy or an adjunctive treatment, ertugliflozin seems to be a reliable and safe option.This narrative review seeks …
Ertugliflozin for treatment of patients with Type 2 diabetes mellitus.
Yang J. Yang J. Expert Rev Clin Pharmacol. 2018 Aug;11(8):747-753. doi: 10.1080/17512433.2018.1503051. Epub 2018 Jul 31. Expert Rev Clin Pharmacol. 2018. PMID: 30025475 Review.
Areas covered: In this paper, the mechanism of action, pharmacokinetics, clinical efficacy, safety, etc., of ertugliflozin have been introduced. Expert commentary: Ertugliflozin offers a novel, therapeutic approach to T2DM. Advantages of ertugliflozin include …
Areas covered: In this paper, the mechanism of action, pharmacokinetics, clinical efficacy, safety, etc., of ertugliflozin have been …
Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.
Cherney DZI, Charbonnel B, Cosentino F, Dagogo-Jack S, McGuire DK, Pratley R, Shih WJ, Frederich R, Maldonado M, Pong A, Cannon CP; VERTIS CV Investigators. Cherney DZI, et al. Diabetologia. 2021 Jun;64(6):1256-1267. doi: 10.1007/s00125-021-05407-5. Epub 2021 Mar 4. Diabetologia. 2021. PMID: 33665685 Free PMC article. Clinical Trial.
AIMS/HYPOTHESIS: In previous work, we reported the HR for the risk (95% CI) of the secondary kidney composite endpoint (time to first event of doubling of serum creatinine from baseline, renal dialysis/transplant or renal death) with ertugliflozin compared with placebo as …
AIMS/HYPOTHESIS: In previous work, we reported the HR for the risk (95% CI) of the secondary kidney composite endpoint (time to first event …
Ertugliflozin for type 2 diabetes.
[No authors listed] [No authors listed] Aust Prescr. 2019 Apr;42(2):70-72. doi: 10.18773/austprescr.2019.018. Epub 2019 Feb 28. Aust Prescr. 2019. PMID: 31048942 Free PMC article. Review. No abstract available.
292 results